ContraVir stock: buy or sell?

CTRV stock price: $4.14 -9.61% At close on June 26th, 2019

Updated on:
June 26th, 2019

1

ContraVir shares plummed -9.61% to $4.14 today. On Friday CTRV rocketed a super good 17.50%. With Wednesday it's been 3 red days in a row.

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections.

Should I buy ContraVir stock?

Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best time to buy them. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

None of our preferred buy setups matches with ContraVir stock situation right now, therefore this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean CTRV will slide in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is ContraVir Pharmaceuticals stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. At Stocks2.com, we found 1 rating published for CTRV stock in the last 30 days.

Is CTRV a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-3-20Maxim GroupBuyHold

ContraVir stock analysis

Daily outlook

Shares of ContraVir Pharmaceuticals plummed a bloodcurdling -9.61% and closed at $4.14.

ContraVir Pharmaceuticals plummed a bloodcurdling -9.61% and closed at $4.14. Since price and SMA50d lines crossed down on April, CTRV fell $-13.29 per share (-76.25%).

CTRV stock chart (daily)

Weekly outlook

ContraVir Pharmaceuticals shares plunged -20.38% this week, ending at $4.14. By mid June CTRV boosted an outstanding 10.24% in just one week.

Since price and 10-weeks moving average lines crossed down last week, CTRV fell $-4.75 per share (-53.43%).

CTRV stock chart (weekly)

ContraVir stock price history

ContraVir stock went public on February 20th, 2014 with a price of $840.001. Since then, CTRV stock sliced a -99.50%, with a yearly average of -19.90%.

1: Adjusted price after possible price splits or reverse-splits.

ContraVir stock historical price chart

CTRV stock reached 52-week highs at $182.00, and all-time highs 2015-10-05 with a price of 3516.8.

ContraVir stock price target

Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' CTRV stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we have not found any price forecast for ContraVir stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

After presenting its last earnings report on November, ContraVir Pharmaceuticals . Unfortunately, reported EPS is not yet available in our database.
CTRV earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/a-0.12n/a
2017-Q2-n/a0.03n/a
2017-Q32017-10-27-0.07-0.08n/a
2017-Q42018-04-03n/an/an/a
2018-Q12018-05-15n/a-0.03n/a
2018-Q22018-08-14n/a-0.38n/a
2018-Q32018-11-14n/a-0.9n/a
2018-Q4-n/an/an/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

In , ContraVir annual turnover to M dollars from marked in . , its profit margin (compared to revenues) to , that is million.

CTRV annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY

Quarterly financial results

Reported quarter income marked $-0.16 M with a profit margin of . Profit margin remained stable a 0.00% compared to previous quarter when profit margin was inf%. When comparing turnover to same quarter last year, ContraVir sales marked a neutral movement and remained constant a nan%. Looking back to recent quarterly results, ContraVir Pharmaceuticals posted 2 positive quarters in a row.
CTRV quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2

ContraVir ownership

When you are planning to buy shares of a stock, it's always worth to have a look its ownership structure.

ContraVir shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 36.42% of all shares.

In case of ContraVir stock, 3.72% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for CTRV stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to ContraVir Pharmaceuticals:

CTRV
Market cap$2.4 M
Total shares0.6 M
Float shares0.5 M
  - Institutional holdings (%)3.7%
  - Insider holdings (%)36.4%
Shares in short selling0.0%

ContraVir summary

Wednesday, June 26th, 2019
Open$4.50
Close$4.14
Day range$4.05 - $4.58
Previous close$4.58
Session gain-9.61%
Average true range$2.78
50d mov avg$8.79
100d mov avg$13.15
200d mov avg$25.73
Daily pattern
Weekly pattern lt03c

ContraVir performance

To measure stock performance is always good to compare with competitors or related stocks. In the following table, we compare ContraVir performance to :
Stock3m6m12m
CTRVContraVir Pharmac...-73.71%-81.52%-95.98%

ContraVir competitors

Unfortunately, we could not find any public company that could be defined as ContraVir Pharmaceuticals competitor. This doesn't mean ContraVir Pharmaceuticals does not have any competitor in the market, it's just we could not detected it.